News from Decision Resources Group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 01, 2016, 08:45 ET DRG Forecasts New Treatment Options Will Revolutionize the Management Of Hemophilia A and Hemophilia With Inhibitors; Hemophilia B Patients are Relatively Well Served.

BURLINGTON, Mass., Dec. 1, 2016 /PRNewswire/ -- Decision Resources Group – Hemophilia patients will have a greater variety of treatment options...


Nov 29, 2016, 06:00 ET DRG and Zephyr Health Announce Partnership to Optimize the Commercial and Market Access Experience for Pharma Stakeholders

Decision Resources Group (DRG), a leading provider of proprietary data products and solutions to the healthcare industry, and Zephyr Health, the...


Nov 14, 2016, 11:29 ET Analysts Available to Comment on the Implications of the Recent US Presidential Election and the Future of the Affordable Care Act and the US Healthcare Industry

Principal Analysts Bill Melville and Paula Wade and Market Analyst Joyce Caruthers are available to discuss the Presidential election and its...


Nov 14, 2016, 10:09 ET Europe has developed into an emerging market for next-generation cosmetic threads fueled by high aesthetic consciousness, recent product innovation, and patient demand for minimally invasive cosmetic procedures

Decision Resources Group finds that demand for a minimally invasive cost-effective alternative to the surgical facelift, favorable demographics,...


Nov 03, 2016, 09:13 ET New MS Therapies & HTA Bodies: What's Driving Such High Rates of Positive Evaluation?

Decision Resources Group finds that 88 percent of health technology assessment (HTA) reviews that examined several recently-launched multiple...


Nov 02, 2016, 09:03 ET The Non-Hodgkin's Lymphoma Drug Market Will Experience Significant Growth, Reaching Over $19 Billion by 2025

New drug approvals have fundamentally changed the non-Hodgkin's Lymphoma (NHL) and chronic lymphocytic leukemia (CLL) market landscape. As...


Nov 01, 2016, 11:00 ET The US Ambulatory Electrocardiography Monitoring Device Market will Experience Strong Growth Through 2025, Driven Primarily by the Shift to Outsourcing and the Increasing Use of Long-Term Monitoring

Decision Resources Group finds that the US ambulatory electrocardiography (ECG) monitoring device market will grow robustly over the next ten...


Oct 25, 2016, 08:32 ET Launches of First Therapies Approved for Spinal Muscular Atrophy and Friedreich's Ataxia Will Revolutionize Treatment and Drive Growth of These Rare Disease Markets

Decision Resources Group finds that the anticipated launches of the first therapies for the treatment of spinal muscular atrophy (SMA) or...


Oct 24, 2016, 08:32 ET The Launch of Merck's Letermovir for Cytomegalovirus Will Transform the Treatment Paradigm for Transplant Recipients, While the Availability of a New Prophylactic Vaccine and Antibody Will Drive Growth in the Respiratory Syncytial Virus Market

Decision Resources Group finds that the number of treatment-eligible patients in the Cytomegalovirus (CMV) and Respiratory Syncytial Virus...


Oct 24, 2016, 08:32 ET Decision Resources Group Expands Global Consulting Services to Asia Pacific

Decision Resources Group (DRG) announced today that it has expanded into Asia Pacific (APAC) with the establishment of a local consulting office in...


Oct 11, 2016, 09:05 ET Decision Resources Group Leads Series B Investment In Context Matters

Context Matters, Inc., the leading provider of health economics data for pharmaceutical industry market access intelligence, and Decision Resources...


Oct 05, 2016, 08:30 ET Identification of new patient populations using validated companion diagnostic tests is a valuable strategy to help ensure payer acceptance of new premium priced targeted therapies and guide oncologists' treatment decisions.

 Decision Resources Group finds that biomarker-targeted therapies with companion diagnostic tests are viewed positively by both oncologists and...


Oct 03, 2016, 08:30 ET More Than Half of Surveyed U.S. and European Psychiatrists Report High Unmet Need for an Efficacious Therapy for Cognitive Impairment Associated with Schizophrenia

 Decision Resources Group finds that, in a survey of U.S. and European psychiatrists, nearly all respondents indicate a moderate to high level...


Sep 29, 2016, 08:30 ET Influx of TAF-Containing Fixed-Dose Combinations From Gilead and Janssen Will Address Patient Needs for Long-Term Safety and Replace Established Treatment Options in the HIV Market

 Decision Resources Group finds that U.S. physicians and payers alike recognize the benefits provided by the new generation of highly...


Sep 28, 2016, 08:30 ET U.S. and European Physicians See a Continued Need for New Osteoporosis Therapies with Improved Safety and Tolerability, and the Potential to Increase Patient Compliance

 Decision Resources Group finds that despite numerous available therapies for osteoporosis, there remains an opportunity for therapies that...


Sep 27, 2016, 09:00 ET First-in-Class Anti-CGRP Monoclonal Antibodies for Migraine Prevention from Eli Lilly, Teva, Amgen/Novartis, and Alder will Drive Market Growth Through 2025

 Decision Resources Group finds that the overall migraine market will grow from approximately $3 billion in 2015 to over $10 billion in 2025...


Sep 26, 2016, 08:30 ET Lower Costs To Payers And Institutions Are Key Drivers For Biosimilar Uptake

 Decision Resources Group finds that prescribing of biosimilars is more widespread in France and Germany than in the United States, even though...


Sep 19, 2016, 08:30 ET Surveyed MCO Pharmacy and Medical Directors Report that the Market-Leading TNF-Alpha Inhibitors Enbrel and Humira Continue to Enjoy the Most Favorable Formulary Coverage in the United States

BURLINGTON, Mass., Sept. 19, 2016 /PRNewswire/-- Decision Resources Group finds that rheumatoid arthritis (RA) biologics and Xeljanz have...


Sep 14, 2016, 08:30 ET How far to go in comparative assessments of health technologies?

 Recent research conducted by DRG Abacus in collaboration with leading academics at Leicester University highlights the benefit of extending...


Aug 29, 2016, 09:00 ET The US Market for Enterprise Solutions Will Increasingly Favor VNA Over Traditional Enterprise PACS as the Market Nearly Triples in Size by 2025

 Decision Resources Group finds that rapid hospital consolidation and the continued shift toward value-based health care have pushed enterprise...


Aug 23, 2016, 08:30 ET Trend Shifts Toward Outpatient Orthopedic Procedures

Decision Resources Group finds that in spite of a longstanding discrepancy between hospital and ASC (Ambulatory Surgical Center) reimbursement, the...


Jul 19, 2016, 08:09 ET Decision Resources Group Launches Intuitive New Platform to Access Real-Time Market Data

Decision Resources Group (DRG), a premier provider of high-value data, analytics and insights products and services to the healthcare industry,...


Jul 05, 2016, 11:00 ET The EU5 Market for Respiratory Drugs is Becoming Increasingly Crowded and Price-Sensitive

 Decision Resources Group finds that access and reimbursement for both chronic obstructive pulmonary disease (COPD) and asthma are becoming...


Jun 30, 2016, 10:00 ET Few Surveyed U.S. and European Neurologists Report High Satisfaction with the Efficacy of Antiepileptic Drugs Approved or Commonly Prescribed to Treat Seizures Associated with Lennox-Gastaut Syndrome

 Decision Resources Group finds that a majority of surveyed neurologists in the United States and Europe report only moderate satisfaction with...


Jun 29, 2016, 09:00 ET Overall Uptake and High Prescribing Rate in Retreatment for Gilead's Harvoni Solidify Its Stronghold on the Hepatitis C Market

 Decision Resources Group finds that despite increasing pressure from competitors, specifically AbbVie's Viekira Pak and Merck's Zepatier,...